Results
2Q26

Earnings Conference Call

August 7, 2026 (Friday)

11:00 a.m. BRT

Portuguese with simultaneous English translation

Webcast

Results 2Q26

Cravinhos, August 6, 2026

Ourofino S.A. ("Company" or "Ourofino") (B3: OFSA3), a company engaged in the research, development, manufacturing and commercialization of veterinary medicines, vaccines and other products for production and companion animals, today announces its financial results for the period ended June 30, 2026 (2Q26).

Investor Relations Department

ri@ourofino.com
(16) 3518-2000
ri.ourofino.com

Marcelo Silva
Philipe Villa
Lislaine Oliveira
& RI team

ourofino saúde animal | Tá bem cuidado

Highlights

- **Consolidated net revenue** reached R$338.7 million in 2Q26, up 30.7% compared to 2Q25, and totaled R$589.1 million in 6M26, an increase of 31.3% compared to 6M25.
- **In Production Animals,** net revenue reached R$252.4 million in 2Q26, up 28.2% compared to 2Q25, and totaled R$428.8 million in 6M26, an increase of 33.1% compared to 6M25.
- **In Companion Animals,** net revenue reached R$49.8 million in 2Q26, up 44.8% compared to 2Q25, and totaled R$94.9 million in 6M26, an increase of 33.7% compared to 6M25.
- **In International Operations,** net revenue totaled R$36.5 million in 2Q26, up 30.5% compared to 2Q25, and reached R$65.4 million in 6M26, an increase of 17.9% compared to 6M25.
- **Consolidated gross profit** reached R$167.4 million in 2Q26, up 25.6%, with a gross margin of 49.4%, down 2.0 p.p. compared to 2Q25. In 6M26, gross profit totaled R$302.4 million, up 34.3%, with a gross margin of 51.3%, representing an expansion of 1.2 p.p. compared to 6M25.
- **Adjusted EBITDA reached** R$60.8 million in 2Q26, up 22.1% compared to 2Q25, and totaled R$105.4 million in 6M26, an increase of 54.0% compared to 6M25.
- **Adjusted Net Income** reached R$15.9 million in 2Q26, down 33.3%, and R$36.7 million in 6M26, up 41.7%.
- **Leverage** ended 2Q26 at 0.43x Net Debt/LTM Adjusted EBITDA, compared to 0.85x at year-end 2025, with 87.0% of debt classified as long-term and an average cost of debt of 8.69%, compared to 8.23% at year-end 2025.
- **At the 2026 Valor Inovação Brasil Awards,** held on August 3, Ourofino Saúde Animal was recognized as one of the most innovative companies in Brazilian agribusiness, ranking second in its industry category.

MANAGEMENT MESSAGE

We concluded the first half of 2026 with consistent results, revenue growth across all business segments, and continued improvement in key operating and financial indicators. This performance reflects the successful execution of our sustainable growth strategy, supported by portfolio expansion, commercial discipline, efficient cost management, and the allocation of resources to initiatives aligned with the Company's strategic priorities.

In 2Q26, net revenue reached R$338.7 million, up 30.7% compared to 2Q25. In 6M26, net revenue totaled R$589.1 million, representing growth of 31.3%. Gross profit reached R$167.4 million in the quarter and R$302.4 million in the first half, increasing 25.6% and 34.3%, respectively. Adjusted EBITDA totaled R$60.8 million in the quarter and R$105.4 million in the first half, growing 22.1% and 54.0%, respectively. Adjusted Net Income amounted to R$15.9 million in 2Q26 and R$36.7 million in 6M26. In the first half, earnings increased 41.7% compared to 6M25, supported by strong commercial performance, portfolio development, and margin and profitability gains achieved throughout the period.

Quarterly results were affected by the discontinuation of certain Companion Animals development projects, which resulted in the recognition of a R$24.4 million accounting provision related to intangible assets. This decision reflects the prioritization of projects with greater alignment to the Company's strategy and stronger value creation prospects. Results were also impacted by inventory loss provisions substantially associated with deviations identified in the manufacturing process. Although these events affected quarterly earnings, they are non-recurring in nature and do not alter the Company's operating fundamentals or long-term growth prospects.

In Production Animals, net revenue reached R$252.4 million in 2Q26 and R$428.8 million in 6M26, representing growth of 28.2% and 33.1%, respectively. Gross profit totaled R$193.7 million, up 36.9%, with a 1.3 p.p. expansion in gross margin, even considering the inventory provisions related to manufacturing process deviations. The segment continued to benefit from products launched in 2025, which increased their participation in the portfolio, supported by commercial initiatives undertaken throughout the period. Recent product launches continue to deliver strong performance and strengthen the Company's competitive position in strategic markets.

In Companion Animals, net revenue reached R$49.8 million in 2Q26 and R$94.9 million in 6M26, increasing 44.8% and 33.7%, respectively. Gross profit totaled R$66.9 million in the first six months of the year, representing growth of 39.6% and a 3.0 p.p. expansion in gross margin. Performance reflected successful commercial execution and the continued advancement of WellPet in the market, contributing to portfolio expansion, strengthening the Company's presence in the segment, and enhancing profitability.

In International Operations, net revenue totaled R$36.5 million in 2Q26 and R$65.4 million in 6M26, increasing 30.5% and 17.9%, respectively. Gross profit reached R$41.8 million in 6M26, maintaining a gross margin of 63.8%. We highlight the strong performance in the Mexican market and the expansion of commercial activities across other Latin American countries, reinforcing the Company's international growth strategy.

It is also important to highlight that business growth has been accompanied by strong operating cash generation. In 6M26, the Company generated **R$183.7 million in operating cash flow**, ending the period with R$369.0 million in cash, financial investments, and cash equivalents. Leverage reached 0.43x Net Debt/LTM EBITDA, reinforcing our ability to finance growth and support our investment agenda focused on innovation and business expansion.

We remain focused on executing our strategic plan by combining growth, innovation, operational efficiency, and disciplined capital allocation. Our first half results reinforce our ability to expand revenue, strengthen profitability, and generate cash. This progress is accompanied by the consistency of our innovation agenda, which was once again recognized with second place in the **Agribusiness category of the 2026 Valor Inovação Brasil ranking**, organized by Valor and Época Negócios and announced after the reporting period. This achievement adds to the recognition recently received by the Company and further demonstrates our ability to develop solutions that create value. We will continue investing in business expansion and increasing our market presence, while maintaining animal health and well-being as a fundamental part of our purpose and our commitment to sustainable long-term value creation.

With Ourofino, they are in good hands.

Kleber Gomes
Chief Executive Officer

Marcelo da Silva
Chief Financial Officer & Investor Relations Director

Financial Highlights

CONSOLIDATED NET REVENUE
6M26
R$589.1 mn
▲ 31.3% vs. 6M25

2Q26 R$338.7 mn ▲ 30.7% vs. 2Q25

CONSOLIDATED GROSS PROFIT
6M26
R$302.4 mn
▲ 34.3% vs. 6M25

2Q26 R$167.4 mn ▲ 25.6% vs. 2Q25

GROSS MARGIN (%)
6M26
51.3%
▲ 1.2 p.p. vs. 6M25

2Q26 49.4% ▼ 2.0 p.p. vs. 2Q25

ADJUSTED EBITDA
6M26
R$105.4 mn
▲ 54.0% vs. 6M25

2Q26 R$60.8 mn ▲ 22.1% vs. 2Q25

ADJ. EBITDA MARGIN
6M26
17.9%
▲ 2.6 p.p. vs. 6M25

2Q26 17.9% ▼ 1.3 p.p. vs. 2Q25

ADJ. NET INCOME
6M26
R$36.7 mn
▲ 41.7% vs. 6M25

2Q26 R$15.9 mn ▼ 33.3% vs. 2Q25

CONSOLIDATED NET REVENUE AND GROSS PROFIT

In 2Q26, consolidated net revenue reached R$338.7 million, up 30.7% compared to 2Q25, while gross profit increased 25.6% to R$167.4 million, with a gross margin of 49.4%. In 6M26, net revenue reached R$589.1 million, an increase of 31.3%, while gross profit totaled R$302.4 million, up 34.3%, with a 1.2 p.p. expansion in gross margin to 51.3%.

Revenue growth in 6M26 reflected, among other factors, the contribution from products launched throughout 2025, accompanied by gross margin expansion during the period. In 2Q26, however, profitability was partially affected by inventory loss provisions, primarily related to deviations identified in the manufacturing process.

R$ million









PRODUCTION ANIMALS

The Production Animals business unit reported net revenue of R$252.4 million in 2Q26, up 28.2% compared to 2Q25, while gross profit reached R$110.8 million, an increase of 20.4%, with a gross margin of 43.9%, down 2.8 p.p. In 6M26, net revenue totaled R$428.8 million, up 33.1% compared to 6M25, while gross profit reached R$193.7 million, an increase of 36.9%, with gross margin expanding by 1.3 p.p. to 45.2%.

In 6M26, this performance reflected the contribution of products launched throughout 2025, which increased their share of the portfolio, combined with commercial initiatives and a more favorable sales mix. In the quarter, margin was partially impacted by inventory loss provisions, primarily associated with deviations identified in the manufacturing process.

R$ million









COMPANION ANIMALS

The Companion Animals business unit reported net revenue of R$49.8 million in 2Q26, up 44.8% compared to 2Q25. Gross profit reached R$34.9 million, an increase of 50.3%, with a gross margin of 70.2%, representing an expansion of 2.6 p.p. In 6M26, net revenue totaled R$94.9 million, up 33.7%, while gross profit reached R$66.9 million, an increase of 39.6%, with a gross margin of 70.5%, representing an expansion of 3.0 p.p.

Performance reflected the commercial initiatives carried out during the period and the Company's entry into the canine ectoparasiticide therapeutic category through the launch of WellPet, expanding its portfolio and strengthening its presence in the Companion Animals market.

R$ million









INTERNATIONAL OPERATIONS

The International Operations business unit reported net revenue of R$36.5 million in 2Q26, up 30.5% compared to 2Q25. Gross profit totaled R$21.6 million, an increase of 19.3%, with a gross margin of 59.2%, down 5.4 p.p.

In 6M26, net revenue reached R$65.4 million, up 17.9% compared to 6M25, while gross profit totaled R$41.8 million, an increase of 16.9%, with a gross margin of 63.8%, down 0.5 p.p.

This performance was supported by the strong results of the Company's operations in Mexico and by commercial initiatives undertaken across Latin American markets, contributing to the expansion of the Company's international presence.

R$ million







Selling, General and Administrative Expenses (SG&A)

R$ Million	2Q25	2Q26	Chg %	6M25	6M26	Chg %
Selling, General & Administrative Expenses (SG&A)	**(76.6)**	**(96.0)**	**25.3%**	**(145.7)**	**(176.7)**	**21.2%**
(-) Non-Recurring Event Adjustments[1]	0.3	0.0	-	0.3	0.0	-
Adjusted Selling, General and Administrative Expenses (Adjusted SG&A)	**(76.3)**	**(96.0)**	**25.8%**	**(145.4)**	**(176.7)**	**21.5%**
Percentages of Net Revenue	-29.4%	-28.4%	1.0 p.p.	-32.4%	-30.0%	2.4 p.p.

[1] In 2Q25 and 6M25, non-recurring adjustments refer to extraordinary expenses related to strategic consulting services.

In 2Q26, adjusted selling, general and administrative expenses totaled R$96.0 million, compared to R$76.3 million in 2Q25, representing growth of 25.8%. As this increase was below net revenue growth of 30.7%, the ratio of these expenses to net revenue decreased from 29.4% to 28.4%, resulting in a dilution of 1.0 p.p.

In 6M26, adjusted selling, general, and administrative expenses totaled R$176.7 million, compared to R$145.4 million in 6M25, representing growth of 21.5%. During the same period, net revenue increased by 31.3%, causing the ratio of these expenses to net revenue to decline from 32.4% to 30.0%, resulting in a dilution of 2.4 p.p.

The changes observed during the periods were mainly attributable to: (i) strategic investments in commercial and marketing structures, in line with the Company's strategic objectives; and (ii) the impact of wage agreement adjustments implemented between the periods.

OTHER EXPENSES

R$ Million	2Q25	2Q26	Chg %	6M25	6M26	Chg %
Other expenses	**(0.0)**	**(23.5)**	**-**	**(1.2)**	**(24.8)**	**-**
(-) Adjustments for Non-Recurring Events[1]	(1.0)	21.3	-	(0.3)	21.3	-
Other expenses adjusted	**(1.0)**	**(2.2)**	**115.8%**	**(1.5)**	**(3.5)**	**128.6%**
Percentages of Net Revenue	-0.4%	-0.6%	-0.2 p.p.	-0.3%	-0.6%	-0.3 p.p.

[1] In 2Q25 and 6M25, non-recurring adjustments refer to prior-period tax credits. In 2Q26 and 6M26, non-recurring adjustments refer to prior-period tax credits and an impairment provision related to intangible assets.

In 2Q26, the Company decided to discontinue certain Companion Animals projects, resulting in the recognition of R$24.4 million in impairment losses on the related assets. For comparability purposes, these effects were adjusted within Other Expenses.

These decisions do not alter the Group's growth strategy, which remains focused on innovation, portfolio expansion and the development of priority markets, in line with the strategic plan.

Adjusted Selling, General, Administrative and Other Expenses — Quarterly View

Adjusted Selling, General, Administrative and Other Expenses — Six-Month View



Research and Innovation Expenses

Research and Development Spending — BRL million



In 6M26, we invested R$40.4 million in research and development, of which R$36.9 million was recognized as expenses, reflecting both the stage of development of the projects and their associated level of innovation. We maintain a continuous investment agenda in research, development and innovation, and quarterly investment levels may vary according to the different stages and cycles of research activities.

EBITDA AND EBTIDA MARGIN

R$ Million	2Q25	2Q26	Chg %	6M25	6M26	Chg %
Adjusted net profit*	23.8	15.9	**-33.3%**	25.9	36.7	**41.7%**
(+) non-recurrent results*	0.7	4.3	-	0.6	4.2	-
(+) Deferred Corporate Income Tax and Social Contribution*	(0.2)	(1.4)	-	(0.2)	(0.8)	-
Net Income for the Period	24.3	18.8	**-22.7%**	26.3	40.1	**52.5%**
(+) Net financial results	4.1	3.5	-14.8%	8.0	4.8	-40.4%
(+)Income Tax and Social Contribution*	12.5	7.2	-42.4%	15.0	19.1	27.3%
(+) Depreciation and amortization	9.6	10.0	4.2%	19.1	20.0	4.7%
EBITDA	50.5	39.5	**-21.8%**	68.4	84.0	**22.7%**
(+) non-recurrent effects	(0.7)	(4.3)	-	(0.6)	(4.2)	-
(+) Others**	0.0	25.5	-	0.6	25.5	-
ADJUSTED EBITDA **	49.8	60.8	**22.1%**	68.4	105.4	**54.0%**
Net Sales Revenue	259.2	338.7	30.7%	448.8	589.1	31.3%
EBITDA margin	19.5%	11.6%	-7.9 p.p.	15.2%	14.3%	-0.9 p.p.
Adjusted EBITDA margin	19.2%	17.9%	-1.3 p.p.	15.3%	17.9%	2.6 p.p.

* In 2Q25 and 6M25, extraordinary expenses and prior-period tax credits were excluded. In 2Q26 and 6M26, prior-period tax credits were excluded. The corresponding tax effects related to the adjustments presented were also excluded in each period.

** In addition to the adjustments mentioned above, Adjusted EBITDA excludes the impairment provision recognized on intangible assets.

Adjusted EBITDA totaled R$60.8 million in 2Q26, representing an increase of 22.1% compared to 2Q25. In the first half of 2026, Adjusted EBITDA reached R$105.4 million, up 54.0% compared to 6M25.

In 6M26, the Adjusted EBITDA margin expanded by 2.6 p.p. We highlight the gains in operating efficiency driven by gross margin improvement, as well as the reduction and dilution of adjusted SG&A expenses.

FINANCIAL RESULTS

R$ Million	2Q25	2Q26	Chg %	6M25	6M26	Chg %
Net financial results	(4.1)	(3.5)	**-14.8%**	(8.0)	(4.8)	**-40.4%**

In 2Q26, net financial expenses totaled R$3.5 million, while in 6M26 net financial expenses amounted to R$4.8 million, representing decreases of 14.8% and 40.4%, respectively, compared to the same periods of the previous year. This improvement was mainly driven by higher income from financial investments, resulting from a higher average balance of cash, cash equivalents and financial investments.

INCOME TAX AND SOCIAL CONTRIBUTION

R$ Million	2Q25	2Q26	Chg %	6M25	6M26	Chg %
Income tax and social contribution	(12.5)	(7.3)	**-41.7%**	(15.1)	(19.2)	**27.3%**
Percentage of Profit Before Income Tax and Social Contribution	34.0%	28.0%	-6.0 p.p.	36,4%	32,4%	-4.1 p.p.

Income tax and social contribution expenses totaled R$19.2 million in 6M26, representing an increase of 27.3% compared to 6M25. The effective tax rate was 32.3%, compared to 36.4% in the same period of the previous year. The calculation of income taxes considers the differences between accounting income and the corresponding taxable income bases.

ADJUSTED NET PROFIT

R$ Million	2Q25	2Q26	Chg %	6M25	6M26	Chg %
Adjuste net profit	23.8	15.9	**-33.3%**	25.9	36.7	**41.7%**
Margin	9.2%	4.7%	-4.5 p.p.	5.8%	6.2%	+0.5 p.p.

As a result of the factors discussed above, Adjusted Net Income totaled R$15.9 million in 2Q26 and R$36.7 million in 6M26, representing a decrease of 33.3% and an increase of 41.7%, respectively, compared to the same periods of the previous year.

CASH POSITION

The Company started 2026 with R$250.8 million in cash and cash equivalents. During the first half of the year, operating cash generation totaled R$183.7 million, reflecting the strong cash generation capacity of its operations.

Financing activities resulted in a net cash outflow of R$56.1 million, primarily related to interest payments, amortization of loans and financing, and other financial disbursements during the period. In addition, the Company invested R$8.5 million in CAPEX and intangible assets.

During the first half, the Company also transferred R$148.1 million to an exclusive investment fund. This fund was established solely to receive investments from the Company and its subsidiaries. The fund's units have daily liquidity, with no lock-up period for redemption, and are settled on a D+0 basis, subject to the terms and conditions set forth in the fund's regulations. The fund is administered by S3 Caceis Brasil DTVM S.A. and managed by Santander Brasil Gestão de Recursos Ltda.

As a result, the Company ended 2Q26 with R$369.0 million in cash and cash equivalents, maintaining an adequate liquidity position to support its operations and investment plan.

Cash Position - BRL million



[1] Operating cash generation differs from the amount presented in the Statement of Cash Flows due to accrued income on financial investments the, which isluded in the ending balance of those investments.

INDEBTNESS

R$ million	12M25	2Q26
Current Assets	52.1	65.8
Non-current Assets	437.4	440.3
Gross Debt	489.6	506.1
(-) Cash, Cash Equivalents and Financial Investments	(250.8)	(369.0)
Dívida Líquida	238.8	137.1
Custo médio da dívida (ano)	8.23%	8.69%
Dívida líquida/EBITDA anual ajustado LTM	0.85x	0.43x

In 2Q26, gross debt totaled R$506.1 million, representing an increase of 3.4% compared to December 2025. Net debt, in turn, decreased from R$238.8 million to R$137.1 million, benefiting from the R$183.7 million in operating cash generation recorded during the first half of the year. Financial leverage ended the period at 0.43x Net Debt/LTM Adjusted EBITDA.

The gross debt profile remains well aligned with the Company's investment agenda, with 87.0% of maturities classified as long-term, of which 34.1% mature in more than five years.

Composition



Leverage



The average cost of debt at the end of the period was 8.69%, representing a spread of 5.46 percentage points below the 14.15% Selic rate observed during the same period.

Cost of Debt vs Selic



Maturity Profile - BRL million



Bank Debt Maturity Profile - BRL million



STATUTORY INCOME STATEMENT

Income Statement (R$ thousands)	2Q25	2Q26	6M25	6M26
Net revenue	259,194	338,673	448,760	589,142
Cost of goods sold	(125,898)	(171,253)	(223,608)	(286,780)
Gross profit	133,296	167,420	225,152	302,362
Sales expenses	(60,395)	(78,427)	(113,644)	(142,321)
Research and development expenses	(15,822)	(18,426)	(28,850)	(36,855)
General and administrative expenses	(16,215)	(17,561)	(32,083)	(34,350)
Other expenses, net	(42)	(23,531)	(1,181)	(24,799)
Operational profit	40,822	29,475	49,394	64,037
Financial revenues	4,604	11,147	8,709	21,198
Financial expenses	(8,746)	(13,601)	(16,647)	(24,773)
Net Derivative Financial Instruments	(3,344)	(1,000)	(3,230)	(229)
Net Foreign Exchange Gains and Losses	3,421	(11)	3,119	(993)
Financial Result	(4,065)	(3,465)	(8,049)	(4,797)
Profit Before Income Tax and Social Contribution	36,757	26,010	41,345	59,240
Income Tax and Social Contribution - Current and Deferred	(12,514)	(7,293)	(15,054)	(19,166)
Net Income for the Period	24,243	18,717	26,291	40,074

STATEMENT OF CASHFLOWS (1/2)

Statement of cashflows (R$ thousands)	6M25	6M26
Cash Flows from Operating Activities		
Net Income for the Period	26,291	40,074
Adjustments for:		
Current and Deferred Income Tax and Social Contribution	15,054	19,166
Expected Credit Losses (Gains) Losses	(26)	838
Provision for Inventory Write-Downs and Losses	13,615	17,586
Depreciation and Amortization	19,032	20,033
Provision for Impairment of Intangible Assets	654	21,271
Gain (Loss) on Disposal of Property, Plant and Equipment	(116)	(60)
Gain (Loss) on Disposal of Intangible Assets.	(666)	4,295
Net Monetary, Foreign Exchange and Interest Variations	11,976	19,999
Derivative Financial Instruments	3,230	229
Provision (Reversal) for Legal Proceedings	(225)	1,453
Long-Term Incentives	2,573	(3,184)
Present Value Adjustment	1,207	1,301
Changes in Working Capital		
Trade Accounts Receivable	116,574	236,077
Inventories	(156,655)	(78,463)
Recoverable Taxes	361	(9,329)
Other Assets	(7,075)	(4,413)
Trade Payables	39,552	(77,765)
Taxes Payable	(5,111)	2,793
Other Liabilities	(6,975)	4,807
Cash Generated from Operations	73,270	216,708
Interest Paid on Loans and Borrowings	(12,091)	(16,971)
Interest Paid on Lease Liabilities	(747)	(1,524)
Income Tax and Social Contribution Paid	(9,965)	(15,473)
Net Cash Generated from Operating Activities	50,467	182,740

STATEMENT OF CASHFLOWS (2/2)

Statement of cashflows (R$ thousands)	6M25	6M26
Cash Flows from Investing Activities		
Investments in Financial Investments	-	(148,090)
Investments in Intangible Assets	(10,792)	(3,529)
Acquisition of Property, Plant and Equipment (PP&E)	(13,630)	(5,250)
Proceeds from the Sale of Property, Plant and Equipment	965	232
Proceeds from the Sale of Intangible Assets	667	0
Net Cash Used in Investing Activities	(22,790)	(156,637)
Cash Flows from Financing Activities		
Proceeds from Loans and Borrowings	67,500	29,992
Repayment of Loans and Borrowings	(21,060)	(18,016)
Lease Payments	(3,434)	(4,356)
Return of Capital to Shareholders	(120,134)	0
Payment of Dividends and Interest on Equity	(35,000)	(62,885)
Settled Derivative Financial Instruments	(1,480)	(880)
Net Cash Used in Financing Activities	(113,608)	(56,145)
Net Increase (Decrease) in Cash and Cash Equivalents	(85,931)	(30,042)
Cash and Cash Equivalents at the Beginning of the Period	233,957	250,821
Foreign Exchange Gains (Losses) on Cash and Cash Equivalents	(427)	(802)
Cash and Cash Equivalents at the End of the Period	147,599	219,977

BALANCE SHEET – ASSETS

Balance sheet (R$ thousands)	12/31/2025	06/30/2026
Assets		
Current Assets	1,023,334	1,106,842
Cash and cash equivalents	250,821	219,977
Short-Term Investments	-	149,026
Derivative Financial Instruments	-	428
Trade Receivables	430,367	327,134
Inventories and Advances to Suppliers	312,128	375,278
Recoverable Taxes	4,628	11,228
Recoverable Income Tax and Social Contribution	12,198	5,994
Related Parties	182	250
Other Assets	13,010	17,527
Non-Current Assets	542,488	507,670
Long-Term Assets	93,770	93,323
Recoverable Taxes	1,268	1,212
Deferred Income Tax and Social Contribution	78,921	80,647
Inventories and Advances to Suppliers	12,310	10,259
Other Assets	1,271	1,205
Permanent Assets	448,718	414,347
Property, Plant and Equipment	342,882	336,013
Intangible Assets	105,836	78,334
Total Assets	1,565,822	1,614,512

BALANCE SHEET – LIABILITIES AND SHAREHOLDER'S EQUITY

Balance sheet (R$ thousands)	12/31/2025	06/30/2026
Liabilities and Shareholders' Equity		
Current Liabilities	288,001	306,390
Trade Payables	97,332	146,588
Derivative Financial Instruments	597	398
Loans and Borrowings	52,144	65,810
Salaries and Social Charges	47,687	47,624
Taxes Payable	14,988	12,111
Income Tax and Social Contribution Payable	-	2,144
Related Parties	2,153	7,789
Dividends and Interest on Equity	52,799	-
Lease Liabilities	7,776	6,898
Sales Commissions	1,218	901
Other Liabilities	11,307	16,127
Non-Current Liabilities	480,964	481,166
Loans and Borrowings	437,439	440,256
Provision for Legal Proceedings	4,969	6,412
Lease Liabilities	6,229	5,354
Other Liabilities	32,327	29,144
Total Liabilities	768,965	787,556
Total Shareholders' Equity	796,857	826,956
Non-Controlling Interests	21	19
Total Liabilities and Shareholders' Equity	1,565,822	1,614,512

ourofino.com
ri.ourofino.com

We develop solutions and services that help feed the world and enhance the longevity of companion animals.

ourofino saúde animal | Tá bem cuidado